US8292141053
© BusinessWire
08.01.2026
SLP
LISTED
NASDAQ
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025.
First Quarter 2026 Financial Highlights (as compared to first quarter 20...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2025
SLP
LISTED
NASDAQ
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.
The event will offer investors and analysts an in-depth look at the Company’s...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026.
Management will host a conference call that...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
09.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidanc...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
01.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025.
Fourth Quarter 2025 Financial...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and managemen...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation – SLP
News Preview
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
So What: If you purchased Simulations P...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
SLP
LISTED
NASDAQ
Simulations Plus to Participate in Upcoming Investor Conferences
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the following investor events...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
SLP
LISTED
NASDAQ
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
SLP
LISTED
NASDAQ
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the I...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation – SLP
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
So What: If you purchased Simulati...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
SLP
LISTED
NASDAQ
Simulations Plus Invests in Clinical Development Technology Company Nurocor
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor.
Founded in 2017, Nurocor offers a cloud-based...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
14.07.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025.
Third Quarter 20...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the t...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue gu...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
SLP
LISTED
NASDAQ
Simulations Plus Releases ADMET Predictor® 13
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, op...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
SLP
LISTED
NASDAQ
Simulations Plus Releases DILIsym® 11
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platfo...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
SLP
LISTED
NASDAQ
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration’s (FDA) recently announced roadmap for reducing animal...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025.
Second Quarter 2025 Financia...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday,...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
SLP
LISTED
NASDAQ
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBan...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
SLP
LISTED
NASDAQ
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February.
The Company is attend...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
SLP
LISTED
NASDAQ
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
SLP
LISTED
NASDAQ
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approve...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024.
First Quarter 2025 Financial...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
SLP
LISTED
NASDAQ
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025.
Manag...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the BTIG Digital Health Forum
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
SLP
LISTED
NASDAQ
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the Stephens Annual Investment Conference
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
SLP
LISTED
NASDAQ
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathc...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
SLP
LISTED
NASDAQ
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024.
Fourth Quarter 2024 Financial Highlights (c...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
SLP
LISTED
NASDAQ
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024.
Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and p...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
SLP
LISTED
NASDAQ
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University o...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
SLP
LISTED
NASDAQ
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future growth following the Company’s recent acqu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
